Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02407223
Registration number
NCT02407223
Ethics application status
Date submitted
30/03/2015
Date registered
2/04/2015
Date last updated
13/03/2019
Titles & IDs
Public title
An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis
Query!
Scientific title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Nonradiographic Axial Spondyloarthritis
Query!
Secondary ID [1]
0
0
CNTO1275AKS3003
Query!
Secondary ID [2]
0
0
CR106995
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Nonradiographic Axial Spondylitis, Ankylosing
0
0
Query!
Condition category
Condition code
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Group 1: Placebo
Treatment: Drugs - Group 2: Ustekinumab 45 mg
Treatment: Drugs - Group 3: Ustekinumab 90 mg
Placebo Comparator: Group 1: Placebo - Participants will receive placebo subcutaneously (SC) at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 milligram (mg) SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with < 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88. NOTE: Intervention Description should have no more than 800 characters.
Experimental: Group 2: Ustekinumab 45 milligram (mg) - Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
Experimental: Group 3: Ustekinumab 90 mg - Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
Treatment: Drugs: Group 1: Placebo
Participants will receive placebo SC at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 mg SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with < 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88.
Treatment: Drugs: Group 2: Ustekinumab 45 mg
Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
Treatment: Drugs: Group 3: Ustekinumab 90 mg
Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Who Achieved Assessment of SpondyloArthritis International Society (ASAS) 20 Response at Week 24
Query!
Assessment method [1]
0
0
ASAS 20 defined as improvement of greater than or equal to (>=) 20 % from baseline and absolute improvement from baseline of 1 on a 0 to 10 centimeter(cm) scale in at least 3 of following 4 domains: Patient's global assessment of disease activity (0 to 10 cm; 0=very well,10=very poor), total back pain (0 to 10 cm; 0=no pain,10=most severe pain), BASFI (self-assessment represented as mean (0 to 10 cm; 0=easy to 10=impossible) of 10 questions, 8 of which relate to participant's functional anatomy and 2 to participant's ability to cope with everyday life), Inflammation (0 to 10 cm;0=none,10=very severe); absence of deterioration (>= 20% and worsening of at least 1 on a 0 to 10 cm scale) from baseline in remaining domain. ASAS20 response based on imputed data using treatment failure (consider non-responders at and after treatment failure),early escape rules (consider non-responder at Week 20 and 24),non-responder[NRI] (missing responses at post baseline visit imputed as non-responder).
Query!
Timepoint [1]
0
0
Week 24
Query!
Secondary outcome [1]
0
0
Percentage of Participants Who Achieved an ASAS 40 Response at Week 24
Query!
Assessment method [1]
0
0
ASAS 40 defined as improvement of >= 40% from baseline and absolute improvement from baseline of at least 2 on 0 to 10 cm scale in at least 3 of following 4 domains: Patient's global assessment of disease activity (0 to 10 cm; 0=very well,10=very poor),total back pain (0 to 10 cm; 0=no pain,10=most severe pain), BASFI (self-assessment represented as mean (0 to 10 cm; 0=easy to 10=impossible) of 10 questions, 8 of which relate to participant's functional anatomy and 2 relate to participant's ability to cope with everyday life), Inflammation (0 to 10 cm; 0=none,10=very severe); no worsening at all from baseline in remaining domain. ASAS40 response based on imputed data using treatment failure(consider non-responders at and after treatment failure),early escape rules(consider non-responder at Week 20 and 24),non-responder[NRI] (missing responses at post baseline visit imputed as non-responder).
Query!
Timepoint [1]
0
0
Week 24
Query!
Secondary outcome [2]
0
0
Percentage of Participants Who Achieved at Least a 50% Improvement From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24
Query!
Assessment method [2]
0
0
The BASDAI is used to measure the ankylosing spondylitis (AS) disease severity. It consists of 6 questions: fatigue, spinal pain, arthralgia (joint pain) or swelling, enthesitis (inflammation of tendons and ligaments), and morning stiffness (2 questions: duration and severity). Each question is an easy to answer 10 centimeter (cm) visual analog scale (VAS), with 0 being none, and 10 being very severe. In order to give each of the 5 symptoms equal weight, the mean of the 2 questions about morning stiffness were added to the total of the remaining 4 scores, and the final BASDAI score (ranging 0-10) is the average of the overall total score. Higher BASDAI score indicates more severe AS symptom. 50% improvement in response based on imputed data using treatment failure(consider non-responders at and after treatment failure),early escape rules(consider non-responder at Week 20 and 24), non-responder[NRI] (missing responses at post baseline visit imputed as non-responder).
Query!
Timepoint [2]
0
0
Week 24
Query!
Secondary outcome [3]
0
0
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24
Query!
Assessment method [3]
0
0
The BASFI is composed with 10 questions (each question is answered with a visual analogue scale 0-10 cm) to assess the disease severity, including the first 8 questions regarding to functional anatomy related activities and the remaining 2 questions related to daily activities of ankylosing spondylitis participants. Each question is a 10cm VAS with a value between 0 (easy) and 10 (impossible). The final BASFI score is the mean of the 10 scores. The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 10. Higher BASFI score indicates more severe functional limitations of the participant due to AS. Early escape rule was applied (measurement value at Week 20 and Week 24 was set as missing).
Query!
Timepoint [3]
0
0
Baseline, Week 24
Query!
Secondary outcome [4]
0
0
Percentage of Participants Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) C-reactive Protein (CRP) Inactive Disease (<1.3) at Week 24
Query!
Assessment method [4]
0
0
ASDAS includes CRP milligram per liter (mg/L); four additional self-reported items (rated on 0-10cm VAS or 0-10 numerical rating scale [NRS]) included total back pain(TBP), duration of morning stiffness (DMS), peripheral pain/swelling and patient global assessment(PGA). ASDAS scores calculated as: ASDAS(CRP) = (0.121*total back pain)+ (0.110*PGA)+ (0.073*peripheral pain/swelling)+ (0.058* DMS)+ (0.579*Ln(CRP+1)). The disease activity, TBP, and peripheral pain/swelling on a numeric rating scale (from 0 (normal) to 10 (very severe)) and DMS on a numeric rating scale (0 to 10, with 0 being none and 10 representing a duration of =>2 hours). Inactive disease is defined as an ASDAS score <1.3. ASDAS (CRP) Inactive Disease is based on imputed data using treatment failure(consider non-responders at and after treatment failure),early escape rules(consider non-responder at Week 20 and 24), NRI (missing responses at post baseline visit imputed as non-responder).
Query!
Timepoint [4]
0
0
Week 24
Query!
Secondary outcome [5]
0
0
Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP) Levels Through Week 24
Query!
Assessment method [5]
0
0
Change from baseline in hsCRP levels was reported. hsCRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. Early escape rule was applied (measurement value at Week 20 and Week 24 was set as missing). Here 'n' signifies the number of participants who were analyzed at each specified timepoints, for each arm, respectively.
Query!
Timepoint [5]
0
0
Baseline, Week 4, 8, 12, 16, 20 and 24
Query!
Secondary outcome [6]
0
0
Percentage of Participants With ASAS 20 Components at Week 24
Query!
Assessment method [6]
0
0
ASAS 20 defined as >= 20% improvement from baseline in 4 individual components of ASAS20: Patient's global assessment (PGA) of disease activity (0 to 10cm; 0=very well,10=very poor), total back pain(0 to 10cm; 0=no pain,10=most severe pain), BASFI (self-assessment represented as mean(0 to10 cm; 0=easy to 10=impossible) of 10 questions, 8 of which relate to functional anatomy and 2 relate to participant's ability to cope with life) and Inflammation (0 to 10cm;0=none,10=very severe).
Query!
Timepoint [6]
0
0
Week 24
Query!
Secondary outcome [7]
0
0
Percentage of Participants Who Achieved ASAS 40 Response at Week 4, 8, 12, 16 and 20
Query!
Assessment method [7]
0
0
ASAS 40 defined as improvement of >= 40% from baseline and absolute improvement from baseline of at least 2 on 0 to10cm scale in at least 3 of following 4 domains: Patient's global assessment of disease activity (0 to 10cm; 0=very well,10=very poor),total back pain (0 to 10cm; 0=no pain,10=most severe pain), BASFI (self-assessment represented as mean (0 to 10 cm; 0=easy to 10=impossible) of 10 questions, 8 of which relate to participant's functional anatomy and 2 relate to participant's ability to cope with everyday life), Inflammation (0 to 10cm;0=none,10=very severe); no worsening at all from baseline in remaining domain. ASAS40 response based on imputed data using treatment failure (consider non-responders at and after treatment failure), early escape rules(consider non-responder at Week 20 and 24),non-responder[NRI] (missing responses at post baseline visit imputed as non-responder).
Query!
Timepoint [7]
0
0
Week 4, 8, 12, 16 and 20
Query!
Secondary outcome [8]
0
0
Percentage of Participants Who Achieved ASAS 20 Response at Week 4, 8, 12, 16 and 20
Query!
Assessment method [8]
0
0
ASAS 20 defined as improvement of >= 20 % from baseline and absolute improvement from baseline of 1 on a 0 to 10 cm scale in at least 3 of following 4 domains: Patient's global assessment of disease activity (0 to 10 cm; 0=very well,10=very poor), total back pain (0 to 10 cm; 0=no pain,10=most severe pain), BASFI (self-assessment represented as mean (0 to 10 cm; 0=easy to 10=impossible) of 10 questions, 8 of which relate to participant's functional anatomy and 2 to participant's ability to cope with everyday life), Inflammation (0 to 10 cm;0=none,10=very severe); absence of deterioration (>= 20% and worsening of at least 1 on a 0 to 10 cm scale) from baseline in remaining domain. ASAS20 response based on imputed data using treatment failure (consider non-responders at and after treatment failure),early escape rules (consider non-responder at Week 20 and 24),non-responder[NRI] (missing responses at post baseline visit imputed as non-responder).
Query!
Timepoint [8]
0
0
Week 4, 8, 12, 16 and 20
Query!
Secondary outcome [9]
0
0
Percentage of Participants Who Achieved at Least a 50% Improvement From Baseline in BASDAI at Week 4, 8, 12, 16 and 20
Query!
Assessment method [9]
0
0
The BASDAI is used to measure the ankylosing spondylitis (AS) disease severity. It consists of 6 questions: fatigue, spinal pain, arthralgia (joint pain) or swelling, enthesitis (inflammation of tendons and ligaments), and morning stiffness (2 questions: duration and severity). Each question is an easy to answer 10 centimeter (cm) visual analog scale (VAS), with 0 being none, and 10 being very severe. In order to give each of the 5 symptoms equal weight, the mean of the 2 questions about morning stiffness will be added to the total of the remaining 4 scores, and the final BASDAI score (ranging 0-10) is the average of the overall total score. Higher BASDAI score indicates more severe AS symptom. 50% improvement in BASDAI based on imputed data using treatment failure(consider non-responders at and after treatment failure),early escape rules(consider non-responder at Week 20 and 24), NRI(missing responses at post baseline visit imputed as non-responders).
Query!
Timepoint [9]
0
0
Week 4, 8, 12, 16, and 20
Query!
Secondary outcome [10]
0
0
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 4, 8, 12, 16 and 20
Query!
Assessment method [10]
0
0
The BASFI is composed with 10 questions (each question is answered with a visual analogue scale 0-10 cm) to assess the disease severity, including the first 8 questions regarding to functional anatomy related activities and the remaining 2 questions related to daily activities of AS participants. Each question is a 10cm VAS with a value between 0 (easy) and 10 (impossible). The final BASFI score is the mean of the 10 scores. The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 10. Higher BASFI score indicates more severe functional limitations of the participant due to AS. Missing data were imputed using early escape rule (measurement value at Week 20 and 24 was set as missing). Here 'n' defined as number of participants who were analyzed at each specified timepoint, for each arm, respectively.
Query!
Timepoint [10]
0
0
Baseline, Week 4, 8, 12, 16 and 20
Query!
Secondary outcome [11]
0
0
Percentage of Participants With ASDAS (CRP) Inactive Disease (<1.3) at Week 4, 8, 12, 16, and 20
Query!
Assessment method [11]
0
0
ASDAS includes CRP mg/L; four additional self-reported items (rated on 0-10cm VAS or 0-10 numerical rating scale [NRS]) included total back pain(TBP), duration of morning stiffness (DMS), peripheral pain/swelling and patient global assessment(PGA). ASDAS scores calculated as: ASDAS(CRP) = (0.121*total back pain)+ (0.110*PGA)+ (0.073*peripheral pain/swelling)+ (0.058* DMS)+ (0.579*Ln(CRP+1)). The disease activity, TBP, and peripheral pain/swelling on a numeric rating scale (from 0 (normal) to 10 (very severe)) and DMS on a numeric rating scale (0 to 10, with 0 being none and 10 representing a duration of =>2 hours). Inactive disease is defined as an ASDAS score <1.3. ASDAS (CRP) Inactive Disease is based on imputed data using treatment failure(consider non-responders at and after treatment failure),early escape rules(consider non-responder at Week 20 and 24), NRI (missing responses at post baseline visit imputed as non-responder).
Query!
Timepoint [11]
0
0
Week 4, 8, 12, 16, and 20
Query!
Eligibility
Key inclusion criteria
- Participants must be classified as having nonradiographic axial spondyloarthritis
(nr-AxSpA) based on 2009 Assessment of SpondyloArthritis International Society (ASAS)
criteria
- Must have an age at nr-AxSpA onset of <= 45 years
- Must have at screening or active inflammation on magnetic resonance imaging (MRI) as
evidenced by the central readers and no radiographic sacroiliitis that fulfills the
1984 modified New York Criteria
- Must have symptoms of active disease at screening and at baseline, as evidenced by
both a BASDAI score of >= 4 and a visual analogue scale (VAS) score for total back
pain of more than or equal to (>=) 4, each on a scale of 0 to 10
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
50
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Have radiographic sacroiliitis fulfilling the 1984 modified New York Criteria
- Have other inflammatory diseases that might confound the evaluations of benefit from
the ustekinumab therapy
- Have received any systemic immunosuppressives or disease-modifying anti-rheumatic drug
(DMARDs) other than methotrexate (MTX), sulfasalazine (SSZ), or hydroxychloroquine
(HCQ) within 4 weeks prior to first administration of study agent
- Have received epidural, intra-articular, intramuscular (IM), or intravenous (IV)
corticosteroids, including adrenocorticotropic hormone during the 4 weeks prior to
first administration of study agent
- Have received prior biologic therapy other than anti-TNFa
- Have received more than 1 prior anti-TNFa agent
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
13/07/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
26/09/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
356
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Geelong
Query!
Recruitment hospital [2]
0
0
- Hobart
Query!
Recruitment hospital [3]
0
0
- Kogarah
Query!
Recruitment hospital [4]
0
0
- Queensland
Query!
Recruitment hospital [5]
0
0
- Woodville South
Query!
Recruitment hospital [6]
0
0
- Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
- Geelong
Query!
Recruitment postcode(s) [2]
0
0
- Hobart
Query!
Recruitment postcode(s) [3]
0
0
- Kogarah
Query!
Recruitment postcode(s) [4]
0
0
- Queensland
Query!
Recruitment postcode(s) [5]
0
0
- Woodville South
Query!
Recruitment postcode(s) [6]
0
0
- Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
Argentina
Query!
State/province [1]
0
0
Buenos Aires
Query!
Country [2]
0
0
Argentina
Query!
State/province [2]
0
0
Ciudad De Buenos Aires
Query!
Country [3]
0
0
Argentina
Query!
State/province [3]
0
0
Ciudad De La Plata
Query!
Country [4]
0
0
Argentina
Query!
State/province [4]
0
0
Ciudad De San Miguel De Tucuman
Query!
Country [5]
0
0
Argentina
Query!
State/province [5]
0
0
Cordoba
Query!
Country [6]
0
0
Belgium
Query!
State/province [6]
0
0
Genk
Query!
Country [7]
0
0
Belgium
Query!
State/province [7]
0
0
Gent
Query!
Country [8]
0
0
Belgium
Query!
State/province [8]
0
0
Leuven
Query!
Country [9]
0
0
Belgium
Query!
State/province [9]
0
0
Liège
Query!
Country [10]
0
0
Belgium
Query!
State/province [10]
0
0
Merksem
Query!
Country [11]
0
0
Czechia
Query!
State/province [11]
0
0
Brno
Query!
Country [12]
0
0
Czechia
Query!
State/province [12]
0
0
Bruntal
Query!
Country [13]
0
0
Czechia
Query!
State/province [13]
0
0
Kladno
Query!
Country [14]
0
0
Czechia
Query!
State/province [14]
0
0
Ostrava
Query!
Country [15]
0
0
Czechia
Query!
State/province [15]
0
0
Pardubice
Query!
Country [16]
0
0
Czechia
Query!
State/province [16]
0
0
Prague 5
Query!
Country [17]
0
0
Czechia
Query!
State/province [17]
0
0
Praha 2
Query!
Country [18]
0
0
Czechia
Query!
State/province [18]
0
0
Praha 4
Query!
Country [19]
0
0
Czechia
Query!
State/province [19]
0
0
Uherske Hradiste
Query!
Country [20]
0
0
Czechia
Query!
State/province [20]
0
0
Zlin
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Boulogne-Billancourt
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Chambray Les Tours
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Echirolles
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Montpellier, Herault
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Paris
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Toulouse
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Bad Nauheim
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Berlin
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Hamburg
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Hannover
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Herne
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Köln
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Olsberg
Query!
Country [34]
0
0
Hungary
Query!
State/province [34]
0
0
Budapest
Query!
Country [35]
0
0
Hungary
Query!
State/province [35]
0
0
Debrecen
Query!
Country [36]
0
0
Hungary
Query!
State/province [36]
0
0
Esztergom
Query!
Country [37]
0
0
Hungary
Query!
State/province [37]
0
0
Kistarcsa
Query!
Country [38]
0
0
Hungary
Query!
State/province [38]
0
0
Nyíregyháza
Query!
Country [39]
0
0
Hungary
Query!
State/province [39]
0
0
Szolnok
Query!
Country [40]
0
0
Hungary
Query!
State/province [40]
0
0
Székesfehérvár
Query!
Country [41]
0
0
Hungary
Query!
State/province [41]
0
0
Veszprem
Query!
Country [42]
0
0
Korea, Republic of
Query!
State/province [42]
0
0
Gwangju
Query!
Country [43]
0
0
Korea, Republic of
Query!
State/province [43]
0
0
Incheon
Query!
Country [44]
0
0
Korea, Republic of
Query!
State/province [44]
0
0
Seoul
Query!
Country [45]
0
0
Mexico
Query!
State/province [45]
0
0
Chihuahua
Query!
Country [46]
0
0
Mexico
Query!
State/province [46]
0
0
Culiacan
Query!
Country [47]
0
0
Mexico
Query!
State/province [47]
0
0
Guadalajara
Query!
Country [48]
0
0
Mexico
Query!
State/province [48]
0
0
Mexico
Query!
Country [49]
0
0
Poland
Query!
State/province [49]
0
0
Bydgoszcz
Query!
Country [50]
0
0
Poland
Query!
State/province [50]
0
0
Szczecin
Query!
Country [51]
0
0
Poland
Query!
State/province [51]
0
0
Torun
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Warszawa
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Wroclaw
Query!
Country [54]
0
0
Russian Federation
Query!
State/province [54]
0
0
Chelyabinsk
Query!
Country [55]
0
0
Russian Federation
Query!
State/province [55]
0
0
Chita
Query!
Country [56]
0
0
Russian Federation
Query!
State/province [56]
0
0
Kemerovo
Query!
Country [57]
0
0
Russian Federation
Query!
State/province [57]
0
0
Kirov
Query!
Country [58]
0
0
Russian Federation
Query!
State/province [58]
0
0
Moscow
Query!
Country [59]
0
0
Russian Federation
Query!
State/province [59]
0
0
Novosibirsk
Query!
Country [60]
0
0
Russian Federation
Query!
State/province [60]
0
0
Orenburg
Query!
Country [61]
0
0
Russian Federation
Query!
State/province [61]
0
0
Petrozavodsk
Query!
Country [62]
0
0
Russian Federation
Query!
State/province [62]
0
0
Sankt-Petersburg.
Query!
Country [63]
0
0
Russian Federation
Query!
State/province [63]
0
0
Saratov
Query!
Country [64]
0
0
Russian Federation
Query!
State/province [64]
0
0
St.Petersburg
Query!
Country [65]
0
0
Russian Federation
Query!
State/province [65]
0
0
Stavropol
Query!
Country [66]
0
0
Russian Federation
Query!
State/province [66]
0
0
Ulyanovsk
Query!
Country [67]
0
0
Russian Federation
Query!
State/province [67]
0
0
Zelenograd
Query!
Country [68]
0
0
Taiwan
Query!
State/province [68]
0
0
Kaohsiung
Query!
Country [69]
0
0
Taiwan
Query!
State/province [69]
0
0
Taichung
Query!
Country [70]
0
0
Taiwan
Query!
State/province [70]
0
0
Tainan
Query!
Country [71]
0
0
Taiwan
Query!
State/province [71]
0
0
Taipei
Query!
Country [72]
0
0
Taiwan
Query!
State/province [72]
0
0
Taoyuan
Query!
Country [73]
0
0
Ukraine
Query!
State/province [73]
0
0
Ivano-Frankivsk
Query!
Country [74]
0
0
Ukraine
Query!
State/province [74]
0
0
Kharkiv
Query!
Country [75]
0
0
Ukraine
Query!
State/province [75]
0
0
Kyiv
Query!
Country [76]
0
0
Ukraine
Query!
State/province [76]
0
0
Lviv
Query!
Country [77]
0
0
Ukraine
Query!
State/province [77]
0
0
Odessa
Query!
Country [78]
0
0
Ukraine
Query!
State/province [78]
0
0
Ternopil
Query!
Country [79]
0
0
Ukraine
Query!
State/province [79]
0
0
Vinnytsya
Query!
Country [80]
0
0
Ukraine
Query!
State/province [80]
0
0
Zaporizhzhya
Query!
Country [81]
0
0
United Kingdom
Query!
State/province [81]
0
0
Bath
Query!
Country [82]
0
0
United Kingdom
Query!
State/province [82]
0
0
Leeds
Query!
Country [83]
0
0
United Kingdom
Query!
State/province [83]
0
0
Leytonstone
Query!
Country [84]
0
0
United Kingdom
Query!
State/province [84]
0
0
London
Query!
Country [85]
0
0
United Kingdom
Query!
State/province [85]
0
0
Norwich
Query!
Country [86]
0
0
United Kingdom
Query!
State/province [86]
0
0
Staffordshire
Query!
Country [87]
0
0
United Kingdom
Query!
State/province [87]
0
0
Torquay
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Janssen Research & Development, LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the efficacy and safety of ustekinumab in adult
participants with active nonradiographic axial spondyloarthritis (nr-AxSpA) measured by the
reduction in signs and symptoms of nonradiographic axial spondyloarthritis (nr-AxSpA).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02407223
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janssen Research & Development, LLC Clinical Trial
Query!
Address
0
0
Janssen Research & Development, LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02407223
Download to PDF